---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-23-000686"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:42:04.193471+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arcturus Q1 net income $50.8M ($1.87 EPS) vs loss year ago; NDA filed for COVID vaccine ARCT-154 in Japan

## Summary
- Revenue $80.3M (up from $5.2M YoY) driven by CSL Seqirus milestones; net income $50.8M vs loss of $51.2M.
- NDA for ARCT-154 (COVID-19 vaccine) submitted in Japan by Meiji Seika Pharma; potential approval later 2023.
- Cash $330.1M; long-term debt eliminated; expects $90M AR collection in Q2; runway extended into early 2026.
- ARCT-032 Phase 1 enrollment complete; expansion to CF patients planned Q3 2023. ARCT-810 Phase 2 interim data on track for later 2023.
- Received $23.6M advance from CSL Seqirus for manufacturing and supply of ARCT-154 in April.

## SEC filing metadata
- accession: 0001193805-23-000686
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380523000686/0001193805-23-000686-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380523000686/e618600_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-23-000686
- JSON: https://secwatch.observer/filing/0001193805-23-000686.json
- Plain text: https://secwatch.observer/filing/0001193805-23-000686.txt

## Key facts
- Earnings Releases
  Arcturus Therapeutics Holdings Inc. reported first quarter ended March 31, 2023 results: revenue $80.3 million.
  - Period: first quarter ended March 31, 2023
  - Revenue: $80.3 million
  - Result: reported results
  source text: Total revenue for the three months ended March 31, 2023, was $80.3 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768224/000119380523000686/0001193805-23-000686-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.